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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.047Aberrant platelet-derived growth factor receptor-a (PDGFRa) signaling is evident in a subset of hepato-
cellular cancers (HCCs). However, its role and regulation in hepatic physiology remains elusive. In the
current study, we examined PDGFRa signaling in liver development and regeneration. We identiﬁed
notable PDGFRa activation in hepatic morphogenesis that, when interrupted by PDGFRa-blocking anti-
body, led to decreased hepatoblast proliferation and survival in embryonic liver cultures.We also identiﬁed
temporal PDGFRa overexpression, which is regulated by epidermal growth factor (EGF) and tumor necrosis
factor a, and its activation at 3 to 24 hours after partial hepatectomy. Through generation of hepatocyte-
speciﬁc PDGFRA knockout (KO) mice that lack an overt phenotype, we show that absent PDGFRa
compromises extracelluar signal-regulated kinases and AKT activation 3 hours after partial hepatectomy,
which, however, is alleviated by temporal compensatory increases in the EGF receptor (EGFR) and the
hepatocyte growth factor receptor (Met) expression and activation along with rebound activation of
extracellular signal-regulated kinases and AKT at 24 hours. These untimely increases in EGFR and Met allow
for normal hepatocyte proliferation at 48 hours in KO, which, however, are aberrantly prolonged up to 72
hours. Intriguingly, such compensation also was visible in primary KO hepatocyte cultures but not in HCC
cells after siRNA-mediated PDGFRa knockdown. Thus, temporal activation of PDGFRa in liver development
is important in hepatic morphogenesis. In liver regeneration, despite increased signaling, PDGFRa is
dispensable owing to EGFR and Met compensation, which is unique to normal hepatocytes but not HCC
cells. (Am J Pathol 2013, 182: 1648e1658; http://dx.doi.org/10.1016/j.ajpath.2013.01.047)Supported by NIH grant 1R01DK62277 (S.P.S.M.) and an Endowed
Chair for Experimental Pathology (S.P.S.M.), by a Cellular Approaches to
Tissue Engineering and Regeneration fellowship (5T32EB001026 to
P.K.A.), and by F31 (F31-DK094611 to P.K.A.).Platelet-derived growth factor receptor-a (PDGFRa) is
a receptor tyrosine kinase (RTK) expressed chieﬂy on
mesenchymal cells including ﬁbroblasts and smooth muscle
cells.1e3 In addition, it also is expressed on other cell types
including neurons and endothelial cells. Its activation is eli-
cited by PDGFs, especially AA and CC, which induce effects
on growth, motility, and survival, thus regulating the function
of these cells.4 After engagement, PDGFRa tyrosine phos-
phorylation can occur at diverse residues to elicit activation of
distinct downstream effectors. Speciﬁcally relevant are
downstream activation of phosphatidylinositide 3-kinases
and AKT, as well as ERK signaling.5e7
Based on gene array studies using RNA from livers at
different stages of gestational development in mice, our labo-
ratory previously reported that PDGFRa expression was at its
highest during early stages, especially around embryonic day
10 (E10) to E12. This coincided with the time of peak hep-
atoblast proliferation, after which the PDGFRa levelsstigative Pathology.
.gradually decreased to low levels.8 In an adult liver, only low
PDGFRa expression is evident, however, its expression is
increased dramatically in a signiﬁcant subset of hepatocellular
carcinomas (HCCs) and its inhibition in human HCC cells
leads to reduced tumor cell proliferation and viability.8,9
It is thus pertinent to investigate further the role and regu-
lation of PDGFRa in liver growth. In the current study, we
investigated the role of this RTK in two major models of
hepatic growth. Liver development was characterized by
regulated hepatic growth and differentiation of bipotential
progenitors or hepatoblasts that compose the early hepatic
bud at approximately E9.5 in mice showed temporal prolif-
eration and resistance to apoptosis, eventually leading to
PDGFRa Signaling in Liver Biologyexpansion of the primitive liver bud.10 During the later stages
of hepatic morphogenesis, additional molecular cues direct
the differentiation of hepatic progenitors to either hepatocytes
or cholangiocytes. Similarly, liver regeneration (LR) after
partial hepatectomy (PHx) is a widely usedmodel to study the
importance of signaling molecules in hepatic growth. The
process of LR requires an orderly interplay betweenmany cell
types and several signaling pathways.11,12 The cellular and
molecular mechanisms responsible for LR show signiﬁcant
redundancy to allow completion of the process as shown by
studies in genetic models or after chemical intervention.
In the current study, we used developing livers from
various gestational stages to verify the expression of
PDGFRa in hepatoblasts and show its activation temporally
during early hepatic development owing to the presence of its
ligands. By using previously characterized embryonic liver
cultures,13,14 we interfered with PDGFRa signaling through
the use of a recently characterized mouse-speciﬁc PDGFRa
blocking antibody15 to address its role in hepatoblast prolif-
eration and survival. We also show that adult murine hepa-
tocytes indeed express PDGFRa, albeit at low levels.
However, after PHx, we observed temporal up-regulation and
activation of PDGFRa and we addressed its regulation during
this process. Through generation of hepatocyte-speciﬁc
PDGFRa knockout mice (KO), by interbreeding ﬂoxed
PDGFRa16 and albumin-cre animals,17 we show that its
conditional loss from hepatocytes is well tolerated. When
subjected to PHx, LR proceeds uneventfully as a result of
compensatory increases in the expression and activation of
epidermal growth factor receptor (EGFR) and the hepatocyte
growth factor receptor, Met. Such redundancy is unique to
LR, but not HCC, growth, making PDGFRa an attractive
therapeutic target. Thus, we show an important role of
PDGFRa in various aspects of liver growth and development.
Materials and Methods
Generation of Pdgfra Conditional Knockout Mice
Homozygous Pdgfra ﬂoxed (exons 1 to 4) and albumin-Cre
mice (both on a C57BL/6 background) were obtained from
Jackson Laboratories (Bar Harbor, ME). Homozygous
ﬂoxed Pdgfra mice were bred to albumin-Cre mice and the
offspring carrying a ﬂoxed Pdgfra allele and albumin-Cre
then were bred to the homozygous ﬂoxed Pdgfra mice.
The mice with the ﬂoxed and ﬂoxed-deleted allele of Pdgfra
henceforth are referred to as Pdgfraloxp/loxp;Alb-Creþ/ or
KO mice and all other genotypes including Pdgfraloxp/loxp;
Alb-Cre/ and Pdgfraloxp/Wt;Alb-Cre/ or Pdgfraloxp/loxp;
Alb-Cre/ are referred to as wild-type (WT) controls.
Animal Studies
All experiments on mice were performed under the strict
guidelines of the NIH and the Institutional Animal Use and
Care Committee at the University of Pittsburgh. TimedThe American Journal of Pathology - ajp.amjpathol.orgpregnantmicewere used to isolate embryos from the E10 stage
of gestational development. En bloc liver from each embryo
was isolated by atraumatic dissection using an Olympus
(Center Valley, PA) stereomicroscope and cultured as an
organ as described previously.13,14 Five livers were cultured in
4% serum and ﬁve livers were cultured in the presence of
50 nmol/L 1E10-IMC, a mouse PDGFRa-blocking antibody,
which was a kind gift fromDr. Nick Loizos (ImClone Systems
Corp., NewYork, NY) and has been reported recently to block
signaling at this concentration.15 Livers were cultured for 72
hours with fresh media containing blocking antibody or 4%
serum alone, replacing the spent media every 24 hours. Livers
were ﬁxed in 10% formalin for parafﬁn embedding and
histologic characterization.
Time pregnant mice also were used to obtain embryos
(n Z 3) from the E12 stage and for ﬁxing in OCT
compound for cryosections.
Eight- to 12-week-old female KO and littermate female
controls were subjected to PHx as described previously.18,19
Mice (n > 3 per genotype) were sacriﬁced at speciﬁed time
points after surgery as indicated in the Results section and in
Figures 3, 5, and 6).
Blood from male or female KO mice along with sex- and
age-matched WT controls was collected at 3 to 10 months
(Table 1) for serum biochemistry. Livers were collected
from these mice for baseline analysis.
Baseline and regenerating livers were harvested and
stored at 80C until use. Livers also were ﬁxed in 10%
formalin to be used for parafﬁn embedding or placed in
OCT compound for cryosections.
Western Blot Analysis
Multiple livers were isolated from embryos from each
developmental stage [E11 to E19, postnatal day (P)1, and
adult] and pooled (n > 10 for E11 to E14; n > 3 for E15 to
adult) for whole-cell lysate extraction in radio immunopre-
cipitation assay buffer.Whole-cell lysateswere prepared from
regenerating liver tissue and from cell cultures and prepared
from independent or pooled (n  3) livers in radio immuno-
precipitation assay buffer for assessment by WB as discussed
elsewhere.18After autoradiography, the ﬁlmswere scanned to
obtain integrated optic densitometry using NIH ImageJ soft-
ware version 1.62. The average integrated optic densitometry
for a protein was compared between the KO and WT groups
and assessed for statistical signiﬁcance by the Student’s t-test,
and a P value less than 0.05 was considered signiﬁcant.
Primary antibodies used for WB included the following:
EGFR (1:200), PDGFRa (1:200), phospho-PDGFRa
Tyr720 (1:100), PDGFRb (1:300), PDGFA (1:200),
PDGFB (1:200), PDGFC (1:200), Met (1:200), and glyc-
eraldehyde-3-phosphate dehydrogenase (1:1000), all from
Santa Cruz Biotechnology (Dallas, TX); phospho-PDGFRa
Tyr572/574 (1:800), phospho-PDGFRa Tyr849 (1:800),
and phospho-PDGFRa Tyr742 (1:800) from Invitrogen
(Grand Island, NY); actin (1:2000) from Millipore (Billerica,1649
Table 1 Serum Biochemistry from KO and WT Mice Depicts No Changes Compared with Controls
Genotype Sex Age, months
Total bilirubin
level, mg/dL
Aspartate transaminase
level, IU/L (normal Z 5e40)
Alanine transaminase
level, IU/L (normal Z 7e56)
WT M 3 0.3 70 31
WT F 8 0.2 53 16
WT F 8 0.3 44 20
KO F 3 0.4 87 23
KO F 3 0.2 82 25
KO M 3 0.3 117 48
KO F 10 0.1 59 16
KO F 10 0.2 61 15
KO F 8 0.3 160 30
F, female; M, male.
Awuah et alMA); and total and p-ERK (Thr202/Tyr204 of ERK1 or
Thr185/Tyr187 of ERK2) (1:1000), and total and p-AKT
Thr308 (1:1000) from Cell Signaling (Danvers, MA).
Real-Time PCR
RNA was extracted from livers using TRIzol (Invitrogen) as
per the manufacturer’s instructions. RNA from each sample
was reverse transcribed with the SuperScript III First-Strand
Synthesis System for real-time PCR with an RNase H
treatment (Invitrogen). In addition, equal amounts of RNA
from three age- and sex-matched KO mouse livers were
pooled to make cDNA. A total of 0.1 mg cDNA along with
Power SYBR-Green PCR Master Mix (Applied Biosystems;
Grand Island, NY) and the appropriate primers (see
following paragraph) were used for each real-time PCR
reaction. The samples were analyzed for each condition in
triplicate to enable statistical analysis. The Applied Bio-
systems StepOnePlus Real-Time PCR System was used for
the transcript analysis with StepOne software version 2.1.
Comparative DDCT was used for data analysis, and calcu-
lations were made without the StepOne software.
The real-time PCR analysis was performed with a liver-
speciﬁc reference gene (cyclophilin-A). Primer efﬁciencies
were performed for each primer, and only similar efﬁcien-
cies were used for analysis. The following real-time PCR
primers were designed using Primer-BLAST (NIH): mouse
Pdgfra forward: 50-TCCTTCTACCACCTCAGCGAG-30;
mouse Pdgfra reverse: 50-CCGGATGGTCACTCTTTAG-
GAAG-30; mouse cyclophilin-A forward: 50-CCCCACC-
GTGTTCTTCGACA-30; mouse cyclophilin-A reverse:
50-TCCAGTGCTCAGAGCTCGAAA-30.
Histology, Immunohistochemistry, and
Immunoﬂuorescence
Four-micron sections from parafﬁn-embedded tissues were
subjected to immunohistochemistry (IHC) for hepatocyte
nuclear factor-4a (HNF4a), proliferating cell nuclear antigen
(PCNA), or TUNEL, as described previously.18 PCNA-
positive hepatocytes were counted using an Axioskop 40
(Carl Zeiss, Cambridge, UK) upright research microscope in1650four randomly selected ﬁelds per section at a magniﬁcation of
400. PCNA counts between WT and KO livers after PHx
were compared for statistical signiﬁcance by the Student’s
t-test, with a P value of less than 0.05 considered signiﬁcant.
For immunoﬂuorescence, cryosections were ﬁxed for
10 minutes in 4% paraformaldehyde, washed in PBS, and
blocked in 2% bovine serum albumin (BSA) for 45 minutes.
Rabbit polyclonal PDGFRa antibody (1:40; Santa Cruz
Biotechnology) and 1:300 mouse monoclonal anti-HNF4a
antibody (PerseusProteomics, Tokyo, Japan) in0.5%BSAwere
incubated for 1 hour followed by washes in 0.5% BSA. Next,
Cy3-conjugated anti-rabbit antibody and Alexa488-conjugated
anti-mouse (Molecular Probes, Grand Island, NY) were applied
at 1:1000 and 1:500 dilutions, respectively, in 0.5%BSA for 30
minutes. Washes were repeated in 0.5% BSA in PBS and
incubated inDAPI for 45 seconds. Sectionswere coverslipped in
Gelvatol and visualized under a Zeiss Axioscope microscope.
Cell Culture and Treatment
HBC-3, a hepatoblast cell line, was a kind gift from Dr. Leslie
Rogler (Albert Einstein College of Medicine, Yeshiva
University, Bronx, NY) and was cultured without inducing
differentiation for obtaining whole-cell lysates as described
elsewhere.20
Human hepatoma cells (Hep3B; ATCC, Manassas, VA)
cultured in serum-free Eagle’s minimum essential medium
were treated with 20 ng/mL EGF (BD, Durham NC), 40 ng/mL
hepatocyte growth factor (Snow Brand, Japan), 25 ng/mL
tumor necrosis factor a (TNFa) (R&D Systems, Minneapolis
MN), and 3 mmol/L/mL EGFR inhibitor (SelleckBio, Hous-
ton TX) for 24 hours. Cells were washed and lysed in radio
immunoprecipitation assay buffer and assessed by WB.
Hep3B cells also were used for siRNA knockdown of
PDGFRa. Cells were cultured in six-well plates in Eagle’s
minimum essential medium with 10% fetal bovine serum.
Cells were serum-starved for synchronization and trans-
fected with 30 nmol/L PDGFRA siRNA (Ambion, Austin,
TX) or control for 6 hours, followed by the addition of 1 mL
Eagle’s minimum essential medium media with 4% fetal
bovine serum. Cells were harvested at 24 hours and 48
hours for WB.ajp.amjpathol.org - The American Journal of Pathology
PDGFRa Signaling in Liver BiologyA modiﬁed two-step collagenase perfusion was used to
isolate hepatocytes from WT and KO mice for hepatocyte
culture as described previously.18 Freshly isolated hepato-
cytes from KO and WT mice were cultured for 2 hours in
MEM containing 10% serum, followed by MEM containing
insulin, selenium, transferrin, dexamethasone, hepatocyte
growth factor, and epidermal growth factor for 24 hours,
and then harvested for whole-cell lysates in radio immu-
noprecipitation assay buffer for WB analysis.
Results
Increased Expression and Activation of PDGFRa during
Early Hepatic Development
To validate previous ﬁndings,8 we used whole-cell lysates
from pooled livers from various prenatal developmental
stages in mice to perform WB analysis for PDGFRa and
PDGFRb. PDGFRa is expressed at high levels in E11 and
E12 livers, with a gradual decrease in protein expression
(Figure 1A). PDGFRb also was expressed similarly
(Figure 1A). To verify whether PDGFRa was expressed in
the epithelial cell compartment of developing liver, we
performed double immunoﬂuorescence for PDGFRa and
HNF4a, a known marker for both hepatoblasts and hepa-
tocytes. Membranous and cytoplasmic localization of
PDGFRa was evident in several HNF4a-positive cells at the
E12.5 stage (Figure 1B). To address PDGFRb localization,
we examined its co-localization with HNF4a, but could not
detect any at E12.5 (Figure 1B). To further substantiate the
expression of PDGFRa in hepatoblasts, we tested HBC-3,The American Journal of Pathology - ajp.amjpathol.orga hepatoblast cell line, which showed comparable
PDGFRa expression with E11 murine livers (Figure 1C).
Next, we tested for the presence of ligands that may be
responsible for engaging PDGFRa during early stages.
Interestingly, although PDGF-CC was the predominant
ligand at early stages, PDGF-AA became more prominent at
E17 and beyond, however, PDGF-CC levels deteriorated
(Figure 1D). PDGF-BB appears to be expressed minimally
throughout liver development.
To address whether PDGFRa signaling is ongoing during
hepatic development, we tested whole- cell lysates for phos-
phorylation of PDGFRa at speciﬁc residues. We identiﬁed
several sites to be phosphorylated in PDGFRa, prominently at
Tyr-572/574, Tyr-720, and Tyr-742 at the E11 to E12 stages,
whereas Tyr-849 showed only limited phosphorylation at the
E11 stage (Figure 1E). To test whether some of the associated
downstream signaling may be active at the corresponding
times, we examined the state of phosphatidylinositide 3-kinase
and AKT signaling because these have been shown to be
regulated by PDGFRa, especially when they are phosphory-
lated at Tyr-742 and other RTKs as well.5 Although total
phosphatidylinositide 3-kinase-p85 and AKT levels remained
relatively unaltered during hepatic development until after
birth, phospho-phosphatidylinositide 3-kinaseep85 and
phospho-AKTeThr308 levels were observed mostly in the
liver lysates at the E11 to E13 stages, followed by a decrease at
all later stages coinciding with the loss of PDGFRa and its
phosphorylated forms (Figure 1F).
Our results therefore suggest that concomitant PDGFRa
and PDGF-C expression induces activation of this RTK to
contribute to hepatic morphogenesis.Figure 1 PDGFRa expression and activation in
early liver development. A: A representative WB
shows the highest expression of PDGFRa at E11 in
liver lysates with a gradual decrease over the
following days of gestational development in mice.
B: Left panel: A representative double immunoﬂu-
orescence with PDGFRa (red) expressed in HNF4a-
positive hepatoblasts (green) cells in E12.5 murine
liver (arrowheads). Right panel: PDGFRb (red)
expressed in noneHNF4a-positive cells (arrows),
whereas HNF4a-positive (green) hepatoblasts
(arrowheads) are negative for PDGFRb. Original
magniﬁcation: 400. C: WB veriﬁes PDGFRa
expression in the HBC3 hepatoblast cell line and E11
liver whole-cell lysate. D: WB shows high PDGF-CC,
but not PDGF-AA, during early liver development,
whereas PDGF-AA levels increase at later stages. E:
WB shows PDGFRa phosphorylation atmultiple sites,
indicating its activation in embryonic livers at early
stages of hepatic development. F: WB shows tyrosine
phosphorylation of phosphatidylinositide 3-kinase
(PI3K)-p85 and AKT, depicting activation at corre-
sponding early stages of hepatic development. Ad,
adult; D1, postnatal day 1; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase.
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Awuah et alBlockade of PDGFRa Signaling in Embryonic Liver
Cultures Reveals Its Role in Hepatoblast Proliferation
and Survival
To further investigate the role of PDGFRa signaling during
early liver development, we used embryonic liver cultures
and PDGFRa-blocking antibody (1E10-IMC, kindly
provided by ImClone), whose efﬁcacy and speciﬁcity
recently were shown.15 Livers isolated from E10 embryos
and cultured in the presence of 1E10-IMC and 4% serum as
compared with 4% serum alone for 72 hours showed fewer
hepatoblasts when examined by IHC for HNF4a (Figure 2).
To determine the mechanism of reduced hepatoblasts, we
tested the organoid cultures for proliferation and any change
in cell viability. The 1E10-IMCetreated embryonic livers
showed dramatically fewer cells in the S-phase as indicated
by IHC for PCNA, suggesting decreased cell proliferation
after 72 hours of PDGFRa blockade (Figure 2). Simulta-
neously, these livers showed a noteworthy increase in the
numbers of TUNEL-positive cells, which is indicative ofFigure 2 PDGFRa blockade in embryonic liver cultures shows its role in
hepatoblast proliferation and survival. Embryonic livers cultured in PDGFRa-
blocking 1E10-IMC monoclonal antibody show decreased numbers of HNF4a-
positive cells by IHC. Inaddition, therewas anotabledecrease in PCNA-positive
cells and increase in numbers of TUNEL-positive cells after 1E10-IMC treatment
compared to cells grown in 4% serum and shown in representative photomi-
crographs. Original magniﬁcation: HNF4a and PCNA,400; TUNEL, 200.
1652ongoing apoptosis (Figure 2). Thus, based on the expression
of PDGFRa mostly in hepatoblasts, it is apparent that
PDGFRa signaling is one of the contributing molecular
pathways in hepatoblast proliferation and viability and
hence in liver growth during ex vivo hepatic morphogenesis.
Temporal Increase in PDGFRa Protein and Activity after
PHx
To determine whether PDGFRa may have a role in another
model of regulated hepatic growth, we assessed its
expression during the process of LR after PHx, especially
because hepatocytes are known to secrete PDGFs during
this process.21 We examined whole-cell lysates from pooled
livers (n  3) at different times after PHx. A dramatic
increase in the PDGFRa protein level was evident at
24 hours during LR, whereas no change in its expression
was observed in samples from sham surgery (Figure 3A).
To verify this observation further, PDGFRa expression was
examined in individual livers from four mice harvested at
24 hours after PHx. All four samples showed a clear
increase in PDGFRa expression at this time during LR
(Figure 3B). Although no other phospho-speciﬁc forms of
PDGFRa were detectable (data not shown), increased
phosphorylation at Tyr-572/574 was observed in regener-
ating livers from 3 to 28 hours, whereas the 24-hour sham
sample lacked such an increase (Figure 3C). Concomitant to
an early increase in phospo (p)PDGFRa, there was
a notable increase in both p-ERK and p-AKT, which indi-
cates the role of PDGFRa in regulating the activity of these
important mediators of LR (Figure 3C).
To determine the mechanism of enhanced protein
expression of PDGFRa, we examined mRNA expression
and identiﬁed a 2.0-fold increase in Pdgfra in pooled
24-hour livers as compared with prehepatectomy samples
(Figure 3D). To address the molecular basis of increased
PDGFRa expression after PHx, we examined the effects of
known growth factors and cytokines that are known to be
critical initiators of LR.12 A human hepatoma cell line,
Hep3B, was treated for 24 hours with hepatocyte growth
factor, EGF, and TNFa, as indicated in Materials and
Methods section, and cells were tested for changes in
PDGFRa protein expression by WB. EGF treatment
brought about noteworthy increases in PDGFRa levels,
which was abrogated by concomitant treatment of cells with
an EGFR inhibitor (Figure 3E). TNFa treatment also led to
a notable increase in total PDGFRa. Thus, EGF and TNFa
induce PDGFRa expression during early LR.
Pdgfra Conditional KO Mice Lack any Overt Phenotype
To address the function of PDGFRa during LR, we
generated hepatocyte-speciﬁc conditional Pdgfra KO mice.
Mice were born in a normal Mendelian ratio and did not
show any apparent phenotype. Genotype was veriﬁed by
the presence of a homozygous ﬂoxed PDGFRa allele andajp.amjpathol.org - The American Journal of Pathology
Figure 3 Temporal increase in PDGFRa expression and activation during LR after PHx. A: Representative WB from pooled livers showed increased PDGFRa
protein expression after PHx, with peak expression evident at 24 hours after PHx. GAPDH veriﬁes comparable loading. B: WB using whole-cell lysates from 4
individual animals showed a notable increase in total PDGFRa at 24 hours after PHx as compared with normal livers at baseline, whereas GAPDH showed
comparable loading. C: Representative WB shows activation of PDGFRa (phosphorylated at Tyr 572 and 574), ERK (phosphorylated at Thr202 and Tyr204 of
ERK1 or Thr185 and Tyr187 of ERK2), and AKT (phosphorylated at Thr308) at various time points after PHx using a site-speciﬁc PDGFRa. SH, sham surgery
sample. D: Real-time PCR showing a twofold increase in Pdgfra 24 hours after PHx (P Z 0.0001). Lysates from Hep3B cells that were treated with various
growth factors for 24 hours show increased PDGFRa expression in response to EGF and TNFa treatment. E: The increase by EGF was abrogated by concomitant
use of EGFR inhibitor AG-1478. GAPDH depicts equal loading. Ctrl, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. *P < 0.05.
PDGFRa Signaling in Liver Biologycre-recombinase by PCR (Figure 4A). The livers from KO
and WT livers showed unremarkable gross differences (not
shown). No differences were observed in liver weight to
body weight ratios between KO and WT mice (Figure 4B),
and serum biochemistry showed insigniﬁcant differences
between WT and KO animals (Table 1). KO livers (2The American Journal of Pathology - ajp.amjpathol.orgmonths old) were used for WB, IHC, and real-time PCR. A
decrease in total PDGFRa was evident in KO by WB as
compared with the control livers (Figure 4C). No changes in
PDGFRb or PDGFRa ligands such as PDGF-AA or PDGF-
CC were observed in the KO versus WT in the livers from
age- and sex-matched littermates (Figure 4C). Because thereFigure 4 Generation of PDGFRa KO mice reveal
a lack of overt phenotype. A: Genotyping PCR iden-
tiﬁes KOs (lanes 2 and 4) by the presence of cre
recombinase (lower panel) andﬂoxed PDGFRa allele
(242 bp) (upper panel). WT controls were identiﬁed
by the absence of cre (lane 3) or the presence of cre
in animals that harbor theWT PDGFRa allele (451 bp)
and ﬂoxed allele (lane 1). The arrows point to the
correct bands of expected sizes and represent
various alleles as noted on the left side of the panel
(WT allele, ﬂoxed allele, and Cre).B: Graph depicting
insigniﬁcant change in liver weight to body weight
(LW/BW) ratios between WT (nZ 6) and KO (nZ 5)
mice at baseline. C: WB shows a signiﬁcant decrease
in total PDGFRa protein in the KO livers. No changes
in the levels of PDGFRb and PDGFRa ligands
including PDGF-AA and PDGF-CC were observed. D:
IHC of WT (left) livers show expression of PDGFRa at
the hepatocyte membrane (arrows). PDGFRa KO
livers (right) show reduced PDGFRa staining, which
was localized to nonparenchymal cells (arrow-
heads). Original magniﬁcation: 400. E: Real-time
PCR showing a signiﬁcant decrease in Pdgfra
expression in KO livers (PZ 0.0001). *P < 0.05.
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Figure 5 Continued proliferation in PDGFRa
KO during LR after PHx. A: Representative WB
veriﬁes abrogation of the surge in PDGFRa
expression in KO livers at 24 hours after PHx as
compared with WT. B: Immunoﬂuorescence shows
PDGFRa (red) localizing to the hepatocyte
membrane at 24 hours after PHx in WT liver,
whereas it is localized to nonparenchymal cells and
is conspicuously absent from hepatocyte mem-
branes in KO. Original magniﬁcation: 400. C:
PCNA IHC in WT liver and KO liver at 48 and 72
hours after PHx shows enhanced nuclear staining
(black arrowheads) and mitosis (arrows) in KO,
especially at 72 hours. PCNA-negative hepatocytes
are indicated by red arrowheads. Original magni-
ﬁcation: 100. D: Bar graph of PCNA index of WT
and KO livers shows comparable cells in the S-
phase at 48 hours whereas a signiﬁcant increase is
observed in KO at 72 hours. *P < 0.05. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
Awuah et alwas signiﬁcant remnant expression of PDGFRa in KO
livers, we next tested PDGFRa by IHC in KO and WT
livers. Indeed, PDGFRa continued to be expressed in non-
parenchymal cells in the KO livers as compared with WT
controls because albumin-cre will speciﬁcally delete the
ﬂoxed gene from hepatocytes (Figure 4D). Real-time PCR
also showed an approximate 50% decrease in PDGFRA
expression in KO livers, which was signiﬁcantly lower than
in littermate controls (Figure 4E).
Pdgfra KO Mice Show Normal Hepatocyte Proliferation
after PHx
Eight-week-old or older female littermate KO and WT mice
were subjected to PHx. Because peak PDGFRa expressionwas
observed at 24 hours, we ﬁrst determined these levels at this
time in KOmice. KO livers lack any increase in PDGFRa at 24
hours after PHx as compared withWT, which indicates that the
predominant increase in PDGFRa protein is in the paren-
chymal cell compartment (Figure 5A). Immunoﬂuorescence at
24 hours during LR shows PDGFRa expression is dramatically
lower in KO mice and is evident in nonparenchymal cells,
whereas WT controls show strong membranous localization in
hepatocytes (Figure 5B).
The KO mice were followed up after PHx for any
morbidity. There appeared to be a temporal-restricted activity
in the KO at approximately 24 hours after PHx, however, all
KO mice recovered from surgery and were indistinguishable
fromWT controls at all later time points. Based on the role of
PDGFRa in liver development and in HCC,8 we compared1654hepatocyte proliferation between the two groups of animals
during LR. We hypothesized that PDGFRa induction and
activation at 24 hours may be one of the upstream signaling
cascades regulating hepatocyte proliferation during LR,
which usually peaks approximately 48 hours after PHx in
C57BL6 mice, although cell-cycle initiation occurs much
earlier. However, we found comparable and high numbers of
hepatocytes in the S-phase as detected by IHC for PCNA at
48 hours in KO and WT livers (Figure 5, C and D).
Intriguingly, at 72 hours, although PCNA staining was
expectedly lower in WT controls, KO mice continued to
display several hepatocytes in the S-phase (Figure 5, C and
D). However, no further growth advantage was evident at
later stages and KO and WT mice had a comparable resto-
ration in hepatic mass at 14 days after PHx.
Pdgfra KO Mice Show No Compensatory Changes in
PDGF Signaling But Show Enhanced EGFR and MET
Expression and Activation during LR
Because of a lack of any defect in cell proliferation in KO
mice at 48 hours and in fact a continued proliferation at
higher than normal levels at 72 hours, we wondered if any
compensatory mechanisms could account for this observa-
tion. We focused on 24 to 72 hours, which represents the
activation times of the cell cycle and of ongoing cell
proliferation during the LR process. First, liver lysates were
assessed for PDGF signaling, which was unremarkable for
any differences in PDGF-AA, PDGF-CC, and PDGFRb,
which has been shown to compensate for PDGFRa lossajp.amjpathol.org - The American Journal of Pathology
Figure 6 Loss of hepatocyte Pdgfra induces
a temporal increase in EGFR and Met expression
and activation at 24 hours after PHx. A: Repre-
sentative WB from pooled livers showed no
changes in protein expression of PDGFRb, PDGF-
AA, or PDGF-BB at various time points after PHx
in KO when compared with WT. B: Representative
WB shows decreased p-AKT and p-ERK in KO
compared with WT at 3 hours during LR. Enhanced
EGFR and MET protein expression in KO livers at 24
hours after PHx coincides with increased p-AKT
and p-ERK at this time in KO compared with WT. C:
Quantiﬁcation of changes in EGFR protein after
PHx shows a 2.5-fold increase in KO livers at 24
hours after PHx, normalized to baseline WT.
D: Quantiﬁcation of changes in MET protein levels
after PHx shows a twofold increase over baseline,
normalized to baseline WT. E: Representative WB
shows enhanced protein expression of phos-
phorylated forms of EGFR and MET as indicated,
especially at 24 hours after PHx. GAPDH, glycer-
aldehyde-3-phosphate dehydrogenase.
PDGFRa Signaling in Liver Biologyin vitro7 (Figure 6A). We next investigated expression for
RTKs, such as EGFR and MET, which are major drivers of
LR and also are associated with hepatocyte proliferation.12
Interestingly, WB showed increased levels of EGFR and
Met protein prominently at 24 hours in the regenerating KO
livers (Figure 6B). Quantiﬁcation after normalization to
loading control revealed an approximately 3.5-fold increase
in EGFR and a 2.5-fold increase in Met greater than the WT
levels at 24 hours (Figure 6, C and D). To address the state
of RTK signaling, we assessed lysates for phosphorylation
of EGFR and MET. Increased levels of Tyr1068-EGFR,
Tyr1173-EGFR, and Tyr1234-Met were observed in lieu of
PDGFRa activation at 24 hours after PHx in KO livers
(Figure 6E). Thus, the anomalous increases in EGFR and
Met expression and activity at 24 hours ensure hepatocyte
proliferation at 48 hours in PDGFRa KO that is comparable
with WT, but the aberration eventually became apparent at
72 hours when proliferation in WT receded whereas KO
hepatocytes continued to proliferate, albeit temporally and
without chronic consequences.Figure 7 EGFR and Met expression is induced after PDGFRa loss in
normal hepatocytes but not in HCC cells. A: Primary hepatocytes isolated
from age- and sex-matched WT and KO livers in culture for 24 hours show
increased expression of EGFR and Met in KO. Densitometric analysis on the
representative WB shows at least a 2.0-fold increase in Met and a 2.5-fold
increase in EGFR levels in the KO hepatocytes. B: A representative WB shows
that PDGFRa siRNA but not control-siRNA transfection of Hep3B cells leads
to a notable decrease in PDGFRa expression, at both 24 hours and 48 hours.
No changes in EGFR or Met were detectable at either time point. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; Si, silencing.Inhibition of PDGFRa Signaling Induces EGFR or Met
Expression in Vitro in Hepatocytes But Not Hepatoma
Cells
To determine whether EGFR and Met are induced globally
on PDGFRa inhibition, we ﬁrst tested the impact of
PDGFRa loss in primary hepatocytes, which were isolated
by collagenase perfusion from WT and KO mice and
cultured for 24 hours as described in Materials and
Methods. A notable increase in total EGFR and Met
expression was evident in KO hepatocytes as compared with
WT hepatocytes after 24 hours in culture (Figure 7A).
Next, we tested the impact of PDGFRa knockdown in
hepatoma cells on EGFR and Met expression. AfterThe American Journal of Pathology - ajp.amjpathol.orgtransfection of PDGFRa siRNA, but not control siRNA, for
either 24 hours or 48 hours, a robust PDGFRa decrease
occurred in Hep3B cells (Figure 7A). However, no change
in either EGFR or Met protein levels were observed at
the corresponding times, indicating that only primary1655
Awuah et alhepatocytes but not HCC cells had the capability to enhance
the expression of the two RTKs on PDGFRa inhibition.
Discussion
PDGFRa, a traditional serum growth factor receptor for
mesenchymal cells, is expressed abundantly in human HCC
cells and is known to induce cell proliferation.1,3,4,6,8,9 To
address the role and regulation of PDGFRa in normal liver
growth, especially in epithelial cells of the liver, we inves-
tigated its status in liver development and in a model of
surgically induced LR.
Previously, we reported the highest expression of the
PDGFRa gene in the earliest stages of hepatic development,
which was identiﬁed by microarray.8 In the current study, we
veriﬁed that hepatoblasts co-express HNF4a and PDGFRa.
Indeed, HNF4a is a surrogate marker of hepatoblasts and
differentiating hepatocytes during hepatic development.22
However, there are other cell types in developing livers
that have been reported to express PDGFRa as well. One
study reported that PFGFRa is expressed in the sub-
mesothelial cell fraction, a precursor of hepatic stellate cells,
and yet another group reported that it is expressed in
a stromal cell that supports erythropoiesis.23,24 Intriguingly,
in the latter study, the investigators identify all PDGFRa-
positive cells to express b1-integrin, which also is known to
be expressed in hepatocytes during early hepatic develop-
ment.25 By using previously characterized embryonic liver
cultures and a mouse PDGFRa blocking antibody, we
showed rampant apoptosis and a decrease in cell prolifera-
tion that eventually led to lower numbers of HNF4a-positive
cells in the culture, suggesting an important role of PDGFRa
in hepatoblast biology. The effect likely is direct owing to
RTK blockade of PDGFRa on the hepatoblasts; additional
in vivo studies currently are ongoing to generate hepatoblast-
speciﬁc conditional knockout using the cre-lox approach.
Indeed, PDGFRa activation is associated with cell survival
and proliferation in several cell types.4,5
However, conditional loss of PDGFRa in hepatocytes
during adulthood was compatible with survival. Increased
PDGFRa expression and signaling during liver development
is highly temporal and is restricted to the early stages of
hepatic development only. Based on the in vitro studies, it is
apparent that loss of PDGFRa at this time remains uncom-
pensated and yields decreased proliferation and increased
apoptosis in embryonic liver cultures. The levels of PDGFRa
recede with progressive hepatic development such that adult
livers have low expression of PDGFRa. The lack of any overt
phenotype in adults lacking hepatocyte-speciﬁc PDGFRa
may in fact be because Alb-cre deletes targeted genes at 4 to 6
weeks after birth,17 a time when PDGFRa is expressed at low
levels and is not actively signaling.
The increase in PDGFRa activation and expression at 3 to 24
hours after PHx is another novel observation. There was an
associated increase in AKT and ERK signaling that is known
to be important in LR and also shown to be downstream1656effectors of PDGFRa signaling.7,26,27 The increased expression
of PDGFRa at 24 hours appears to be downstream of EGF and
TNFa, which are both active during the LR initiation process,
especially in the PHx model.11,21 At the same time PDGFRa is
activated as evident by its phosphorylation status, which may
result from an autocrinemechanism because PDGFs are known
to be secreted by hepatocytes during LR, although no changes
in their total protein is observed during LR.21 To address its
role, we generated PDGFRa-conditional KO that lacked
PDGFRa in hepatocytes. These mice showed no overt
phenotype and this is not surprising because of the normally
low expression of PDGFRa in the liver and perhaps because of
the existing redundancy in RTK signaling pathways. Also,
remnant expression of PDGFRa in KO is caused by its pres-
ence in nonparenchymal cells such as endothelial cells and
hepatic stellate cells.23,28 When the KO mice were subjected to
PHx,we observed a notable decrease in PDGFRa expression at
3 and 24 hours, supporting the increased expression and
activity of PDGFRa in hepatocytes during the early LR period.
Simultaneously, a decrease in p-ERK and AKT activity was
evident at 3 hours in the KO. Intriguingly, however, increased
p-AKT and p-ERK levels were evident in the KO at 24 hours,
which corresponded to increased EGFR and Met expression
over the WT levels. Met and EGFR are paramount in normal
LR and in regulating hepatocyte proliferation.29,30 This
excessive EGFR and Met expression and activity in the
absence of PDGFRa enabled comparable hepatocyte prolifer-
ation at 48 hours in KO andWT. These ﬁndings again highlight
the existing molecular redundancy that exists in the normal LR
process where blockade of a single signaling pathway is readily
compensated by an alternate signaling cascade.12,31 However,
this untimely and nonscheduled aberration appears to be
responsible for transiently prolonging hepatocyte proliferation
in PDGFRa in KO at 72 hours, as reﬂected by increased
hepatocytes in the S-phase when compared with WT where
proliferation has receded. However, all later time points in KO
are unremarkable for any proliferative changes when compared
with the WT. These observations also highlight a ﬁne balance
that exists between various signaling mechanisms during the
process of normal LR.11,12
Intriguingly, however, the inverse relationship between
EGFR and PDGFRa also was described in EGFR suppression
studies. shRNA-mediated silencing of EGFR during LR led to
an increase in both gene and protein expression of PDGFRa.30
Similarly, the deletion of Pdgfra lead to enhanced stimulation
of the EGFR pathway in mouse embryonic ﬁbroblasts.7 The
exact mechanism of the relationship between PDGFRa and
EGFRwill need further studies, although EGFR and PDGFRa
may be interacting physically, as shown to occur between
EGFR and PDGFRb.32e34
Hepatic ﬁbrosis and cirrhosis as a result of chronic liver
diseases are precursors of HCC. Approximately 80% of all
HCCs have underlying cirrhosis.35 In fact, chronic liver
injury leads to hepatocyte death, inﬂammation, ﬁbrosis,
oxidative stress, and hepatocyte proliferation.36 The regen-
erating nodules that occupy the cirrhotic liver are consideredajp.amjpathol.org - The American Journal of Pathology
PDGFRa Signaling in Liver Biologycritical for maintenance of hepatic function, but proliferation
in these nodules in a suboptimal environment also makes
them prone to genotoxic insult, eventually evolving into
dysplastic nodules and HCC. Because several signaling
pathways are commonly relevant in LR and HCC, molec-
ular targeting can be a concern in HCC in chronic liver
diseases. Thus, it is critical to identify targets that may be
dispensable for LR but are critical for HCC. In our current
study, we show that PDGFRa signaling, which previously
was shown to be a valid, biologically relevant, therapeutic
target in HCC,8,9,37 may be dispensable for LR because of
redundancy with other RTKs such as EGFR and Met.
Intriguingly, such redundancy is unique to normal hepato-
cytes and not HCC cells because siRNA-mediated PDGFRa
knockdown in Hep3B cells did not induce the expression of
these RTKs. Although additional studies will be necessary,
we propose that selective targeting of PDGFRa in eligible
HCC patients may be efﬁcacious, even in chronic liver
diseases, without concern that hepatic functions will be
impaired. Humanized PDGFRa-blocking antibody is in fact
on the horizon for the treatment of various cancers.15,38,39
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